Illumina is one of our 'future hero' investments. The company accounts for about 80% of the emerging DNA sequencing market. The Human Genome Project was responsible for the first sequencing of human DNA - it took 13 years, 1990 to 2003, and cost $2.7 billion. Since then technology has improved so much that it now takes less than a day and only costs $600.
Last week Illumina unveiled their newest sequencing machine, with significant improvements. It will be capable of generating more than 20 000 whole genomes a year, a 2.5x increase over the older model. Thanks to improved technology and quicker processing times, operating costs drop from $600 to $200 per sequence. The benefits do come with a slightly higher price tag though. The machine will cost $1.25 million, up from the current model's $950 000.
It's exciting to see the rapid changes in this emerging industry. As costs drop quickly, we will start to see DNA-tailored medication. The industry has massive growth potential. Illumina's share price has been rising lately on this news.